GLP-1 & Weight Management

• First-in-class synthetic 39-amino acid dual GIP/GLP-1 receptor agonist ('twincretin') with imbalanced receptor binding profile and biased signaling at GLP-1R
• FDA-approved May 2022 (Mounjaro for T2D), November 2023 (Zepbound for obesity), December 2024 (Zepbound for OSA) — extensively validated in 2,000+ peer-reviewed publications
• Engineered with 2 Aib residues (DPP-4 resistance), C20 fatty diacid albumin-binding moiety (5-day half-life), enabling once-weekly dosing; cryo-EM structures elucidated for both GIPR-Gs and GLP-1R-Gs complexes

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR. Research demonstrates up to 24.2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists. Phase 2 data shows 86% liver fat reduction in MASLD and -2.02% HbA1c reduction in type 2 diabetes.

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR. Research demonstrates up to 24.2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists. Phase 2 data shows 86% liver fat reduction in MASLD and -2.02% HbA1c reduction in type 2 diabetes.

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR. Research demonstrates up to 24.2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists. Phase 2 data shows 86% liver fat reduction in MASLD and -2.02% HbA1c reduction in type 2 diabetes.

• First-in-Class Triple Agonist: 39 aa peptide simultaneously activating GIPR (EC₅₀ 0.0643 nM), GLP-1R (EC₅₀ 0.775 nM), GCGR (EC₅₀ 5.79 nM), GIP backbone with Aib/C20 fatty diacid, t½ 6 days, once-weekly
• Superior Efficacy: Phase 2 obesity 24.2% weight loss at 48 weeks (12 mg), MASLD 82.4% liver fat reduction, T2D HbA1c -2.02%, 100+ publications, 100% ≥5% weight loss responders
• Clinical Development: Phase 3 TRIUMPH program (5,800+ participants), TRIUMPH-4 showed 26.4-28.7% weight loss at 68 weeks, TRANSCEND cardiovascular outcomes program, dose-dependent GI AEs

Cagrilintide - Long-acting amylin analog activating AMY1R/AMY2R/AMY3R and CALCR receptors. ≥98% purity (HPLC). Half-life 159-195 hours. For laboratory research only.